Atrial Fibrillation Pipeline Drugs and Companies Insight Report

27 Apr 2021
www.globenewswire.com
Small molecular drug
Los Angeles, USA, April 26, 2021 (GLOBE NEWSWIRE) -- Atrial Fibrillation Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments The global demand for Atrial Fibrillation treatment options is emerging swiftly, driven by consumption in major emerging markets. As more growth opportunities will surge, several companies such as ARCA biopharma, AbbVie, Hanmi Pharmaceutical, Espero BioPharma, Vivasc Therapeutics, HUYA Bioscience, Novartis, Acesion Pharma, and others are working on Atrial Fibrillation pipeline. DelveInsight’s “Atrial Fibrillation Pipeline Insight” report provides comprehensive insights about 17+ companies and 17+ pipeline drugs in the Atrial Fibrillation pipeline landscapes. It comprises Atrial Fibrillation pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Atrial Fibrillation therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Atrial Fibrillation pipeline products. Some of the key takeaways of the Atrial Fibrillation Pipeline Report Get an overview of pipeline landscape @ Atrial Fibrillation Clinical Trials Analysis Atrial Fibrillation is an irregular heartbeat that can lead to blood clots, stroke, heart failure and other heart-related complications. The atria beat chaotically and irregularly out of coordination with the ventricles of the heart. Atrial Fibrillation Emerging Drugs Etripamil, the lead investigational product, is developed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered through a nasal spray that may shift the current treatment paradigm for many patients with Paroxysmal supraventricular tachycardia (PSVT) in the emergency department to the at-home setting. Milestone is conducting a thorough development program for etripamil, with Phase 3 trials underway in PSVT, and intends to start a Phase 2 proof-of-concept trial in patients with atrial fibrillation with rapid ventricular rate, with subsequent studies anticipated in other conditions where calcium channel blockers are utilised. OMT-28 is a stable synthetic small molecule analogue of the natural omega-3 fatty acid metabolite 17, 18-EEQ, which has a structure optimised to confer efficacy, safety, and oral availability. The compound has shown its anti-arrhythmic, cardioprotective, and anti-fibrotic potential in different in vivo models. Presently, it is in phase 2 of clinical trials for the Atrial Fibrillation treatment. HBI-3000 is a multi-ion channel blocker with effects on INa-Peak, INa-Late, ICa, L, and IKr with similar in vitro potencies across these several ion channels in human atrial cardiomyocytes. It is being developed by HUYA Bioscience International® (HUYABIO™) for the conversion of recent-onset Atrial Fibrillation. It is currently undergoing phase 1 of clinical trials. It is based on the inhibition of SK channels - ion channels present in the atria that regulate the cardiac rhythm. Inhibiting these ion channels with a functionally atrial selective drug help avoid harmful effects on the ventricles. Targeting the SK channels thereby comprises a novel and promising approach for an effective treatment for Atrial Fibrillation with an anticipated higher safety and tolerability profile. For further information, refer to the detailed report @ Atrial Fibrillation Pipeline Therapeutics Scope of Atrial Fibrillation Pipeline Drug Insight Key Questions regarding Current Atrial Fibrillation Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customised pipeline report @ Atrial Fibrillation Drugs Pipeline Report Related Reports DelveInsight's Atrial Fibrillation - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Atrial Fibrillation - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Atrial Fibrillation in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. DelveInsight’s Atrial Flutter Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Cystic fibrosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight’s Fibrocystic Breast Condition Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. About DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  It also proffers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.